Merck Serono ditches cladribine, leaving MS franchise exposed
This article was originally published in Scrip
Merck Serono has finally given up on cladribine, its oral candidate for relapsing remitting multiple sclerosis. It has withdrawn the product from the approval process in the US and will cease to pursue approval everywhere else. It will also withdraw the product from sale in Russia and Australia, where it is marketed as Movectro.
Register for our free email digests: